Zomelis Met 50mg/1000mg Tablet is a combination oral antidiabetic medication containing Metformin hydrochloride 1000mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps achieve optimal blood glucose regulation in patients inadequately controlled on monotherapy or lifestyle interventions alone. Zomelis Met is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as rare occurrences of hypoglycemia and lactic acidosis. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Dose adjustments should be guided by clinical response and tolerability to minimize risks and maximize therapeutic benefits.